Cargando…
A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials
We describe a Bayesian adaptive design for early phase cancer trials of a combination of three agents. This is an extension of an earlier work by the authors by allowing all three agents to vary during the trial and by assigning different drug combinations to cohorts of three patients. The primary o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505662/ https://www.ncbi.nlm.nih.gov/pubmed/28706582 http://dx.doi.org/10.3844/amjbsp.2016.1.11 |
_version_ | 1783249458758156288 |
---|---|
author | Tighiouart, Mourad Li, Quanlin Piantadosi, Steven Rogatko, Andre |
author_facet | Tighiouart, Mourad Li, Quanlin Piantadosi, Steven Rogatko, Andre |
author_sort | Tighiouart, Mourad |
collection | PubMed |
description | We describe a Bayesian adaptive design for early phase cancer trials of a combination of three agents. This is an extension of an earlier work by the authors by allowing all three agents to vary during the trial and by assigning different drug combinations to cohorts of three patients. The primary objective is to estimate the Maximum Tolerated Dose (MTD) surface in the three-dimensional Cartesian space. A class of linear models on the logit of the probability of Dose Limiting Toxicity (DLT) are used to describe the relationship between doses of the three drugs and the probability of DLT. Trial design proceeds using conditional escalation with overdose control, where at each stage of the trial, we seek a dose of one agent using the current posterior distribution of the MTD of this agent given the current doses of the other two agents. The MTD surface is estimated at the end of the trial as a function of Bayes estimates of the model parameters. Operating characteristics are evaluated with respect to trial safety and percent of dose recommendation at dose combination neighborhoods around the true MTD surface. |
format | Online Article Text |
id | pubmed-5505662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-55056622017-07-11 A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials Tighiouart, Mourad Li, Quanlin Piantadosi, Steven Rogatko, Andre Am J Biostat Article We describe a Bayesian adaptive design for early phase cancer trials of a combination of three agents. This is an extension of an earlier work by the authors by allowing all three agents to vary during the trial and by assigning different drug combinations to cohorts of three patients. The primary objective is to estimate the Maximum Tolerated Dose (MTD) surface in the three-dimensional Cartesian space. A class of linear models on the logit of the probability of Dose Limiting Toxicity (DLT) are used to describe the relationship between doses of the three drugs and the probability of DLT. Trial design proceeds using conditional escalation with overdose control, where at each stage of the trial, we seek a dose of one agent using the current posterior distribution of the MTD of this agent given the current doses of the other two agents. The MTD surface is estimated at the end of the trial as a function of Bayes estimates of the model parameters. Operating characteristics are evaluated with respect to trial safety and percent of dose recommendation at dose combination neighborhoods around the true MTD surface. 2016-08-25 2016 /pmc/articles/PMC5505662/ /pubmed/28706582 http://dx.doi.org/10.3844/amjbsp.2016.1.11 Text en http://creativecommons.org/licenses/by/3.0/ This open access article is distributed under a Creative Commons Attribution (CC-BY) 3.0 license. |
spellingShingle | Article Tighiouart, Mourad Li, Quanlin Piantadosi, Steven Rogatko, Andre A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials |
title | A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials |
title_full | A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials |
title_fullStr | A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials |
title_full_unstemmed | A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials |
title_short | A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials |
title_sort | bayesian adaptive design for combination of three drugs in cancer phase i clinical trials |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505662/ https://www.ncbi.nlm.nih.gov/pubmed/28706582 http://dx.doi.org/10.3844/amjbsp.2016.1.11 |
work_keys_str_mv | AT tighiouartmourad abayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials AT liquanlin abayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials AT piantadosisteven abayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials AT rogatkoandre abayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials AT tighiouartmourad bayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials AT liquanlin bayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials AT piantadosisteven bayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials AT rogatkoandre bayesianadaptivedesignforcombinationofthreedrugsincancerphaseiclinicaltrials |